Home › Markets › Health Care › TECH

Bio-Techne Corp (TECH)

TECH trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$72.48
-0.11% on the day
Market cap
$11.4B
Large cap
Revenue · 2025
$1.2B
+5.2% on 2024
Net income · 2025
$73.4M
6.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerTECH on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000842023
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inMN

Financials · 2025

LineValue
Revenue$1.2B
Net income$73.4M
Operating income$102.3M
Net margin6.0%
Operating margin8.4%
Revenue growth+5.2%
Cash$172.9M
Total assets$2.5B
P/E (computed)154.9×
P/S (computed)9.3×

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-08-24
Latest quarterly / interim10-Q2026-05-06
Latest current report8-K2026-09-23
Latest proxyDEFA14A2026-09-14

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.0%
1 month+0.3%
3 months+1.1%
Year to date+23.3%
1 year+21.6%
From 52-week high-0.1%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
PCVXVaxcyte Inc.$66.80-5.45%$10.5B
IBRXImmunityBio Inc.$9.80-3.16%$10.4B
HALOHalozyme Therapeutics Inc.$109.62-1.31%$12.4B
TWSTTwist Bioscience Corporation$151.33-0.35%$10.0B
KRYSKrystal Biotech Inc.$321.16-3.29%$9.5B
NBIXNeurocrine Biosciences Inc.$135.13-4.41%$13.7B
QGENQiagen N.V. Common Shares$45.44+0.29%$9.4B
KYMRKymera Therapeutics Inc.$106.68-4.82%$8.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier